A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) has announced the publication of research validating the ability of its xB3 platform to cross the intact blood-brain barrier (BBB) and its localization in a variety of brain cell types. The company said research shows that the xB3 platform can cross intact BBB and enter intracellular organelles within neurons, glia and microglia in the brain. It said the data from a study published on June 2 in the Frontiers in Neuroscience provide evidence for the utility of xB3 peptide (previously known as MTfpep) as a platform technology for delivery of recombinant and chemically conjugated drug across the BBB.
Enveric Envisions Using Mushrooms and Cannabis to Help Patients The cannabis biotech company explains why the acquisition of MagicMed makes sense, additional capital raises and the Psybrary. Stocks quotes in this article: ENVB
Cannabinoid biotech company Enveric Biosciences Inc. (ENVB) recently decided to expand its product offering to its targeted patient group by bringing psychedelic medicine company MagicMed into its fold.
Enveric acquired privately held MagicMed recently in a deal valued at $30 million. Enveric s CEO David Johnson is moving into the Chairman role, while MagicMed s leader, Dr. Joseph Tucker, will be named the new CEO of the combined company.
I had the chance to speak with Dr. Tucker and find out why this cannabis biotech company felt the need to expand into psychedelics.